Laboratory biomarkers in Alzheimer's disease (Q36926040)

17 August 2017

1 reference

title

Laboratory biomarkers in Alzheimer's disease (English)

1 reference

17 August 2017

0 references

0 references

Joshua R Steinerman

1

1 reference

PubMed ID

17764627

17 August 2017

Lawrence S Honig

series ordinal

2

1 reference

17 August 2017

1 September 2007

1 reference

Current Neurology and Neuroscience Reports

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

5

1 reference

17 August 2017

381-387

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-007-0059-6

17 August 2017

0 references

cites work

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11910-007-0059-6

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11910-007-0059-6

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11910-007-0059-6

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

12 December 2020

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

1 reference

12 December 2020

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

1 reference

12 December 2020

Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

1 reference

12 December 2020

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

1 reference

12 December 2020

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

1 reference

12 December 2020

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

1 reference

12 December 2020

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

12 December 2020

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

1 reference

12 December 2020

Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group

1 reference

12 December 2020

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

1 reference

12 December 2020

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

1 reference

12 December 2020

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

1 reference

12 December 2020

The role of biomarkers in clinical trials for Alzheimer disease

1 reference

12 December 2020

Clinical evaluation as a biomarker for Alzheimer's disease

1 reference

12 December 2020

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

12 December 2020

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

1 reference

12 December 2020

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

1 reference

12 December 2020

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele

1 reference

12 December 2020

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

1 reference

12 December 2020

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

12 December 2020

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

1 reference

12 December 2020

Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.

1 reference

12 December 2020

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

12 December 2020

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

1 reference

12 December 2020

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

1 reference

12 December 2020

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

1 reference

12 December 2020

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry

1 reference

12 December 2020

Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk

1 reference

12 December 2020

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

1 reference

12 December 2020

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

1 reference

12 December 2020

Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia

1 reference

12 December 2020

Autoantibodies to amyloid-beta and Alzheimer's disease.

1 reference

12 December 2020

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

1 reference

12 December 2020

Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.

1 reference

12 December 2020

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

1 reference

12 December 2020

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

1 reference

12 December 2020

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

1 reference

12 December 2020

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

1 reference

12 December 2020

The AD7C-NTP neuronal thread protein biomarker for detecting Alzheimer's disease

1 reference

12 December 2020

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

1 reference

12 December 2020

Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease

1 reference

12 December 2020

Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.

1 reference

12 December 2020

Biomarkers: Potential Uses and Limitations

1 reference

12 December 2020

Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.

1 reference

12 December 2020

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.

1 reference

12 December 2020

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease

1 reference

12 December 2020

10.1007/S11910-007-0059-6

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17764627